相关实验视频

Updated: Sep 17, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

回到未来:预测个体阿尔茨海默病的进展

Robin Sandell¹, Justin Torok¹, Kamalini G Ranasinghe²

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.

Research square

|June 30, 2025

概括

这项研究引入了一种新的算法,即基于阶段的网络扩散 (StaND),用于预测个体阿尔茨海默病 (AD) 的进展. 根据StaND模型的患者特异性tau传播,改善了阿尔茨海默病和其他神经退行性疾病的精准医学.

科学领域:

神经科学是一个神经科学.
计算生物学计算生物学
医疗成像医学成像

背景情况:

阿尔茨海默氏症 (AD) 病理学涉及tau神经纤维状结通过大脑网络传播.
病理传播的个体变异性需要个性化治疗方法.

研究的目的:

引入基于阶段的网络扩散 (StaND),这是一个用于预测阿尔茨海默病患者特异性进展的新算法.
通过模拟个别的种植和传播动态,实现精准医学方法.

主要方法:

利用了阿尔茨海默病神经成像计划中650名受试者的数据.
开发了StaND,将统计分期与生物物理建模相结合,以估计疾病阶段,tau播种,聚合和传播率.
应用该模型来预测横截面和纵向区域tau分布.

主要成果:

在预测tau分布方面,StaND的表现优于基准模型.
推断的tau播种模式揭示了空间异质性,速率参数解释了临床变异性.
确定了两种独特的tau种植原型,具有独特的临床和人口特征.

结论:

StaND提供了一种强大的新方法,用于理解和预测阿尔茨海默病的时空动态.
该算法的方法适用于其他神经退行性疾病,为研究和临床应用提供了广泛的潜力.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的疾病.生物物理建模生物物理建模精准医学是一门精准的医学.统计建模统计建模

更多相关视频

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...